U.S. LIPOSOMAL DOXORUBICIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

U.S. Liposomal Doxorubicin Market Size and Share Analysis- 2026 To 2033

The U.S. Liposomal Doxorubicin Market size is anticipated to grow at a CAGR of 6.8% with USD 500 Mn in 2026 and is expected to reach USD 780 Mn in 2033. The market is growing with the rising recurrent ovarian cancer burden, continued use of pegylated liposomal doxorubicin in oncology treatment protocols, increasing demand for safer anthracycline delivery systems, and expanding availability of therapeutically equivalent generic formulations. According to the U.S. FDA label, DOXIL liposomal infusion is indicated for ovarian cancer after platinum-based

Key Takeaways

• The generic segment is projected to account for the largest share of 61.5% in 2026. The segment growth is due to the cost-effective oncology treatment access, payer preference, and wider ANDA-based availability. Generic drugs account for about 91% of all U.S. prescriptions.
• The ovarian cancer segment is projected to account for the largest share of 46.8% in 2026. The segment’s growth is attributable to the established use in recurrent ovarian cancer after platinum-based chemotherapy. In 2026, around 12,450 deaths are expected due to ovarian cancer in the U.S.
• California is projected to account for the largest share of 12.4% in 2026. The growth is due to the large oncology patient pool and higher specialty treatment demand. The American Cancer Society estimates 206,500 new cancer cases and 61,280 cancer deaths in California in 2026.

Segmental Insights 

Which Generic Segment Dominates the Market?

On the basis of drug type, the generic segment accounts for the largest U.S. Liposomal Doxorubicin Market share of 61.5% in 2026. The growth of the segment is mainly driven by the rising demand for cost-effective oncology therapies, wider payer preference for lower-cost alternatives, and increasing availability of FDA-approved generic liposomal doxorubicin products. According to the U.S. FDA, 9 out of 10 prescriptions filled in the U.S. are for generic drugs, highlighting the strong role of generics in improving treatment affordability and access.

Generic liposomal doxorubicin is widely used as it offers a therapeutically equivalent alternative to branded Doxil for approved oncology indications, including ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma. The Association for Accessible Medicines reported that generics and biosimilars account for around 90% of U.S. prescriptions but only 13.1% of prescription drug spending, making them important for oncology cost containment.

Ovarian Cancer Segment to Secure the Largest Share 

On the basis of cancer type, the ovarian cancer segment accounts for the largest U.S. Liposomal Doxorubicin Market share of 46.8% in 2026. The segment’s growth is owing to the FDA-approved use of liposomal doxorubicin in ovarian cancer after progression or recurrence following platinum-based chemotherapy, continuing recurrent disease burden, and the need for treatment options in patients who have exhausted initial chemotherapy regimens.

SEER estimates 21,010 new ovarian cancer cases and 12,450 deaths in the U.S. in 2026. It reported that 54% of ovarian cancer cases are diagnosed at distant stage, thereby indicating a high burden of advanced disease. The FDA label also includes clinical trial evidence in ovarian cancer including a randomized trial of 474 patients comparing DOXIL liposomal infusion with topotecan after platinum-based chemotherapy. These factors support the continual use in later-line treatment pathways.

In August 2024, Lupin Limited launched Doxorubicin Hydrochloride Liposome Injection in the U.S., following FDA approval secured by alliance partner ForDoz Pharma. The generic Doxil equivalent targets ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma, with USD 40.9 million sales.

Market Drivers

Rising Innovations in Generic Oncology Injectables are Transforming the U.S. Liposomal Doxorubicin Market

The U.S. liposomal doxorubicin market is being transformed by continued generic competition, regulatory pathways for complex injectables, as well as increasing attention to sterile injectable quality. Liposomal doxorubicin is a complex oncology injectable, and market access depends not only on clinical demand but also on manufacturing consistency, FDA approval, vial availability, therapeutic equivalence, and institutional contracting. Generic entry is important because oncology providers and hospital pharmacies seek reliable sources for older injectable cancer therapies that remain clinically relevant but are vulnerable to supply constraints.

In June 2025, Alembic Pharmaceuticals announced that it received USFDA final approval for its ANDA for Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL and 50 mg/25 mL single-dose vials. The company stated that the approved ANDA is therapeutically equivalent to Baxter’s reference listed drug, Doxil Liposome Injection, and cited an estimated U.S. market size of US$29 million for the twelve months ending March 2025.

Pegylated Liposomal Nanocarrier Technology: A Major Breakthrough in U.S. Liposomal Doxorubicin Market

Pegylated liposomal nanocarrier technology represents the core breakthrough behind liposomal doxorubicin. The technology encapsulates doxorubicin inside liposomes, helping alter pharmacokinetics and drug distribution compared with conventional doxorubicin.

The FDA label highlights the pharmacokinetic distinction of DOXIL liposomal infusion, reporting plasma clearance of total doxorubicin from DOXIL at 0.041 L/h/m² at a 20 mg/m² dose, compared with 24 to 35 L/h/m² following administration of conventional doxorubicin hydrochloride. This difference supports the clinical rationale for using liposomal drug delivery in oncology, particularly where prolonged circulation and altered tissue distribution are desirable.

The technology is also important from a safety-management perspective. The FDA label carries warnings for cardiomyopathy and infusion-related reactions, and it notes that acute infusion-related reactions occurred in 11% of patients with solid tumors across multiple studies. Therefore, innovation is not only focused on efficacy but also on formulation quality, infusion protocols, monitoring, and institutional readiness. Such innovations are expected to accelerate the U.S. liposomal doxorubicin market growth during the forecast period.

Current Events and Their Impact on the U.S. Liposomal Doxorubicin Market

U.S. Liposomal Doxorubicin Market Trends

• Rising adoption of generic liposomal doxorubicin improves treatment affordability and oncology drug access across U.S. hospitals and specialty clinics.
• Increasing recurrent ovarian cancer burden supports demand, as liposomal doxorubicin is indicated for ovarian cancer progressing after platinum-based chemotherapy.
• Preference for liposomal formulations is increasing due to controlled circulation and drug-delivery advantages over conventional doxorubicin. DailyMed states that at least 90% of liposomal doxorubicin remains liposome-encapsulated during circulation, supporting targeted delivery benefits.
• Broader clinical use across ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma strengthens the product’s treatment relevance. DOXIL safety data reflects exposure in 1,310 patients, including 239 ovarian cancer patients, 753 AIDS-related Kaposi’s sarcoma patients, and 318 multiple myeloma patients.
• ACS reported that about 18.6 million people in the U.S. were living with a history of cancer as of January 1, 2025. This number is projected to exceed 22 million by 2035. This trend supports the sustained oncology treatment demand which includes later-line therapies as well as supportive infusion infrastructure.

Regional Insights

California Liposomal Doxorubicin Market Trends

California is an important state market owing to its large population, major academic medical centers, cancer research ecosystem, as well as high oncology treatment volumes. The state has several major cancer institutions and hospital systems that support the use of specialized oncology injectables like liposomal doxorubicin. Demand is supported by ovarian cancer treatment pathways, hematology-oncology practices, and institutional procurement through hospital networks.

Texas Liposomal Doxorubicin Market Trends

Texas is a key growth market because of its large population base, major cancer hospitals, growing oncology service capacity, and presence of high-volume infusion centers. The state’s cancer-care ecosystem supports demand for later-line chemotherapy products, including liposomal doxorubicin, particularly in gynecologic oncology and hematology-oncology settings.

Who are the Major Companies in U.S. Liposomal Doxorubicin Market

Some of the major key players in U.S. Liposomal Doxorubicin Market are Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.

Key News

• In May 2026, Sun Pharmaceutical Industries voluntarily recalled one U.S. batch of Aisling DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL due to glass particles. The recall covered 675 vials with no adverse events reported. It involved return or replacement arrangements.
• In July 2024, ForDoz Pharma Corp. received U.S. FDA approval for DOXOrubicin Hydrochloride Liposome Injection in 20 mg/10 mL and 50 mg/25 mL strengths. The product, ForDoz’s first liposomal injectable for the U.S. market, is distributed by Lupin Pharmaceuticals.

Market Report Scope 

Analyst Opinion

• The U.S. liposomal doxorubicin market growth is driven by real oncology treatment need, not only product availability. Cancer care costs in the U.S. were estimated at USD 208.9 billion in 2020, showing the pressure to use effective and cost-managed therapies across oncology settings.
• Ovarian cancer is the core driver for the demand because several patients are diagnosed at advanced stages and need later-line treatment options. SEER data shows only 22% of ovarian cancer cases are localized at diagnosis, while 54% are distant-stage cases with a 31.5% five-year relative survival rate.
• Liposomal doxorubicin continues to hold relevance because it is used across ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. The generic shift further supports market access, as generics represented 90% of U.S. prescriptions filled in 2024 but only 12% of total prescription drug spending.

Market Segmentation

• By Drug Type (Revenue, USD Mn, 2021-2033)
  • Branded
  • Generic
• By Cancer Type (Revenue, USD Mn, 2021-2033)
  • Ovarian Cancer
  • AIDS-related Kaposi’s Sarcoma
  • Multiple Myeloma
  • Others
• By Region (Revenue, USD Mn, 2021-2033)
  • California
  • Texas
  • Florida
  • New York
  • Pennsylvania
  • Illinois
  • Ohio
  • Georgia
  • North Carolina
  • Michigan
  • New Jersey
  • Virginia
  • Washington
  • Arizona
  • Others
• Key Players
  • Johnson & Johnson
  • Baxter International Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Reddy’s Laboratories, Inc.

Sources

Primary Research Interviews

• Medical oncologists
• Hematologists
• Gynecologic oncologists
• Oncology pharmacists
• Hospital procurement managers
• Cancer treatment center administrators
• Specialty drug distributors
• Injectable drug manufacturers
• Key opinion leaders (KOLs) in oncology and chemotherapy delivery

Databases

• U.S. Food and Drug Administration (FDA)
• National Cancer Institute (NCI)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Centers for Medicare & Medicaid Services (CMS)
• ClinicalTrials.gov
• U.S. National Library of Medicine
• American Cancer Society Cancer Statistics Center

Magazines

• OncLive
• Cancer Network
• The ASCO Post
• Pharmaceutical Technology
• BioPharma Dive
• Fierce Pharma

Journals

• Journal of Clinical Oncology
• The Lancet Oncology
• JAMA Oncology
• Cancer
• Clinical Cancer Research
• Annals of Oncology
• Cancer Chemotherapy and Pharmacology
• International Journal of Pharmaceutics

Newspapers

• The New York Times
• The Wall Street Journal
• Reuters
• Bloomberg
• The Washington Post

Associations

• American Society of Clinical Oncology (ASCO)
• American Association for Cancer Research (AACR)
• National Comprehensive Cancer Network (NCCN)
• American Cancer Society
• Community Oncology Alliance
• Association for Clinical Oncology
• Oncology Nursing Society

Public Domain Sources

• Company Annual Reports and Investor Presentations
• FDA Drug Labels, Approval Packages, and Orange Book Listings
• Government Health Agency Publications
• Cancer Registry Publications
• Clinical Trial Registries Such as ClinicalTrials.gov
• Hospital and Oncology Center Publications
• Public Reimbursement and Pricing Databases
• Press Releases and Regulatory Filings

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years